Arrowhead Research | ARWR - Capitale Sociale E Riserve





Capitale Sociale E Riserve Cambiamento Data
Agios Pharmaceuticals USD 1.11B 84M 2026-03
Alnylam Pharmaceuticals USD 1.08B 286.2M 2026-03
Anika Therapeutics USD 133.9M 9.56M 2026-03
Arrowhead Research USD 613.98M 45.56M 2026-03
Heron Therapeutics USD 9.14M 4.15M 2026-03
Incyte USD 5.62B 455.37M 2026-03
Ionis Pharmaceuticals USD 491.41M 2.32M 2026-03
Ligand Pharmaceuticals USD 997.32M 19.89M 2026-03
Merck USD 45.88B 6.73B 2026-03
Moderna USD 7.41B 1.24B 2026-03
Nektar Therapeutics USD 89.83M 4.75M 2025-12
Novartis USD 38.93B 7.2B 2026-03
Sarepta Therapeutics USD 1.51B 364.48M 2026-03
TG Therapeutics USD 583.13M 64.89M 2026-03
Ultragenyx Pharmaceutical USD -236M 156M 2026-03
Vertex Pharmaceuticals USD 19.36B 696.1M 2026-03
Xencor USD 515.63M 119.95M 2026-03